Seroprevalence of hepatitis b and hepatitis C markers among children and adolescents in the south brazilian region - metropolitan area of Florianópolis, Santa Catarina

Brazilian Journal of Infectious Diseases

Volumn 14, Issue 1, 2010, Pages 60-65

  Voigt, Andréia Royer ^a   Neto, Miguel Strazer ^a   Spada, Celso ^a   Treitinger, Arício ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Anti HBc; Anti HBs; Anti HCV; HBsAg; HBV; HCV; Seroprevalence

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY;

ADOLESCENT; ADOLESCENT HEALTH; ANTIBODY TITER; ARTICLE; BRAZIL; CHILD; CHILD HEALTH; CONTROLLED STUDY; DIAGNOSTIC KIT; DISEASE MARKER; FEMALE; HEPATITIS B; HEPATITIS C; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MICROPARTICLE ENZYME IMMUNOASSAY; PREVENTIVE HEALTH SERVICE; SCHOOL CHILD; SEROPREVALENCE; SEX DIFFERENCE;

EID: 77954811550     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1413-86702010000100012     Document Type: Article

References (36)

1. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunnol 2005; 5:215-29.
2. Bond WW, Petersen NJ, Favero MS. Viral hepatitis B: aspects of environmental control. Health Lab Sci 1977; 14:235-52.
3. Alter MJ, Margolis HS. The emergence of hepatitis B as a sexually transmitted disease. Med Clin North Am 1990; 74:1529-41.
4. Tahan V, Karaca C, Yildirim B et al. Sexual transmission of HCV between spouses. Am J Gastroenterol 2005; 100:821-24.
5. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94:153-6.
6. Fattovich G, Stroffolini T, Zagni I & Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127:(suppl)S35-S50.
7. World Health Organization. Programmes and projects - Immunization service delivery and accelerated disease control - New vaccines and technologies - Hepatitis B. 2008. (http://www.who.int/immunization_delivery/new_vaccines/hepb/en/index.html).
8. World Health Organization. Programmes and projects - Media centre - Fact sheet n° 164 - Hepatitis C. 2000. (http://www.who.int/mediacentre/factsheets/fs164/en/).
9. Hepatite B: Glossário de doenças. Programa Nacional de Hepatites Virais. (http://portal.saude.gov.br/portal/saude/visualizar_texto.cfm?idtxt=27151) (in portuguese).
10. Hepatite C: Glossário de doenças. Programa Nacional de Hepatites Virais. (http://portal.saude.gov.br/portal/saude/visualizar_texto.cfm?idtxt=27220)(in portuguese).
11. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Material instrucional para capacitação em vigilância epidemiológica das hepatites virais. Brasília, DF: Ministério da Saúde, 2008 (in portuguese).
12. Chávez JH, Campana SG, Haas P. Panorama de hepatite B no Brasil e no Estado de Santa Catarina. Rev Panam Salud Publica 2003; 14(2):91-6.
13. Miranda LVG, Passos ADC, Figueiredo JFC et al. Marcadores sorológicos de hepatite B em indivíduos submetidos a exams de sangue em unidades de saúde. Journal of Public Health 2000, 34(3):286-91.
14. Andrade AFB, Silva MO, Silva SGC et al. Seroprevalence of hepatitis B and C virus markers among blood donors in Rio de Janeiro, Brazil, 1998-2005. Mem Inst Oswaldo Cruz 2006, 101(6):673-6.
15. Nascimento MC, Mayaud P, Sabino EC et al. Prevalence of hepatitis B and C serological markers among first-time blood donors in Brazil: a multi-center serosurvey. J Med Virol 2008; 80:53-7.
16. Treitinger A, Spada C, Ferreira LAP et al. Hepatitis B and hepatitis C prevalence among blood donors and HIV-1 infected patients in FlorianópolisFlorianópolis-Brazil. Braz J Infect Dis 2000; 4(4):192-6.
17. Rosini N, Mousse D, Spada C. Treitinger A. Seroprevalence of HBsAg, anti-HBc and anti-HCV in Southern Brazil, 1999- 2001. Braz J Infect Dis 2003; 7(4):262-7.
18. Treitinger A, Spada C, Silva EL et al. Prevalence of serologic markers of HBV and HCV infection in HIV-1 seropositive patients in Florianópolis-Brazil. Braz J Infect Dis 1999;3(1):1-5.
19. Pereira RARA, Mussi ADH, Silva VCA, Souto FJD. Hepatitis B virus infection in HIV-positive population in Brazil: results of a survey in the state of Mato Grosso and a comparative analysis with other regions of Brazil. BMC Infect Dis 2006; 6:34.
20. Motta VT, Wagner MB. Bioestatística. Caxias do Sul, RS: Educs; São Paulo, SP: Robe Editorial, 2003. (in portuguese).
21. Silveira TR, Fonseca JC, Rivera L et al. Hepatitis B seroprevalence in Latin America. Pan Am J Public Health 1999; 6(6):378-83.
22. Inquérito nacional de hepatites virais. 2009. (http://www.hepto.com) (in portuguese).
23. Centers for Disease Control. Recommendation of the Immunization Practices Advisory Committee (ACIP). Recommendations for protection against viral hepatitis. Morb Mortal Wkly Rep 1985; 34:313-24, 329-35.
24. Centers for Disease Control. Recommendations of the Immunization Practices Advisory Committee. Update on hepatitis B prevention. Morb Mortal Wkly Rep 1987; 38:353-60, 366.
25. International Group. Immunization against hepatitis B. Lancet 1988; 1:875-876.
26. West DJ, Calandra GB. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 1996; 14(11):1019-27.
27. Banatvala J, Van Damme P, Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine 2001; 19:877-85.
28. Wang RX, Boland GJ, Hattum JV, De Gast GC. Long term persistence of T cell memory to HBsAg after hepatitis B vaccination. World J Gastroenterol 2004; 10(2):260-3.
29. McMahon BJ, Bruden DL, Petersen KM et al. Antibody levels and protection after hepatitis B vaccination: results of a 15- year follow-up. Ann Intern Med 2005; 142:333-41.
30. Dentinger CM, McMahon BJ, Butler JC et al. Persistence of antibody to hepatitis B and protection from disease among Alaska natives immunized at birth. Pediatr Infect Dis J 2005; 24:786-92.
31. Zanetti AR, Mariano A, Romanò L et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005; 366:1379-84.
32. Ferreira CT, Silveira TR. Viral hepatitis prevention by immunization. J. Pediatr 2006; 82(3)suppl:S55-S66.
33. Giambi C, Bella A, Barale A et al. A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines. BMC Infect Dis 2008; 8:100.
34. Bialek SR, Bower WA, Novak R. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis b vaccine beginning at birth: a 15-year follow-up study. Pediatr Infect Dis J 2008; 27:881-5.
35. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Sistema nacional de vigilância em saúde: relato ́rio de situação Santa Catarina. Brasília, DF: Ministério da Saúde, 2007 (in portuguese).
36. Focaccia R, Conceição OJ, Sette HJ et al. Estimated prevalence of viral hepatitis in general population of the municipality of São Paulo, measured by a serologic survey of a stratified, randomized and residence-based population. Braz J Infect Dis 1998; 2:269-84.